Search for a trial

A national study for blood based response monitoring of newly diagnosed DLBCL patients

The primary objective is to collect liquid biopsy samples of patients with newly diagnosed DLBCL/HGBCL to develop a blood based assay allowing biomarker driven treatment in the future. The secondary objectives are to collect clinical data and pre-…

Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts

Dose Escalation (GEN3009 for R/R B-cell NHL Including CLL/SLL):- Determine the MTD with and/or determine the RP2D of GEN3009- Evaluate safety and tolerability of GEN3009Expansion (GEN3009 for R/R, DLBCL, FL, and CLL Cohorts):-Evaluate (preliminary)…

A Phase 1, Open-Label, Dose-Escalation, Safety, Tolerability, and Preliminary Efficacy Study of MCLA-145 in Participants With Advanced or Metastatic Malignancies

Primary:- To determine the safety, tolerability, and dose-limiting toxicities (DLTs) of MCLA-145 and to determine an MTD and/or the RDE in advanced or metastatic solid tumors or B-cell lymphomas.Secondary:- To explore preliminary antitumor activity…

The Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination with Other Agents in Subjects with B-cell Non-Hodgkin Lymphoma

This study has been transitioned to CTIS with ID 2023-504805-35-00 check the CTIS register for the current data. Dose Escalation PhasePrimary - Evaluate the safety and tolerability of epcoritamab in combination with other agents Secondary-…

A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

This study will evaluate the efficacy of brentuximab vedotin in combination with lenalidomide and rituximab among subjects with relapsed or refractory CD30-positive (CD30 expression >=1%) or CD30 <1% (CD30 expression <1%) DLBCL.

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator*s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

This study has been transitioned to CTIS with ID 2023-504830-23-00 check the CTIS register for the current data. Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)